Medicortex is working towards the identification of brain injury biomarkers and their incorporation into a quick diagnostic kit and accurate detection that can be used by all healthcare professionals with ease. The ideal kit will not only diagnose the presence of brain injury, it will also quantify in the future its severity and indicate the precise treatment needed. In addition, the kit could become a key component of efficacy testing in all future clinical trials in TBI, and it will be used by the first responders.
The lack of a truly effective diagnostic test for brain injury is a major unmet need in modern medicine. The main problem is that, while there are often tell-tale symptoms, many TBI victims do not present any brain injury symptoms, and consequently receive treatment either too late or not at all. In addition, repeated mild TBI can lead to a condition called Chronic Traumatic Encephalopathy (CTE). Victims of CTE, who have lately been in the news due to their involvement in high profile athletics, still have no way of detecting or tracking their condition. Therefore, it is critical that a core group of TBI biomarkers be identified.
Medicortex intends to look for a new biomarker never looked at before (not a protein/cytokine), looking for it in one or more of the body fluids that were less investigated for this purpose. The idea is to make a relatively easy test to be used, for example, in emergency response situations like car accidents, sport injuries and combat situations. It can also help in cases were the injured person cannot describe the injury such as babies and people in coma.
Medicortex is targeting glycoproteins and cellular proteins/enzymes, which are exposed to each other due to cells being damaged. We are looking for proteolytic breakdown products. This product can either increase or decrease following the injury, but must be in correlation with the severity of the injury.